Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics


Posted on: 15 Nov 16

LA JOLLA, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company developing precision medicines for cancer, today announced it will be presenting two posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2016), taking place November 29 – December 2, 2016 in Munich.  The presentations will feature preclinical data from Kura Oncology’s KO‒947 ERK inhibitor and menin-MLL inhibitor programs.  Abstracts are currently available online at the European Cancer Organisation website (www.ecco-org.eu/Events/ENA2016).

Posters
Date & Time: Nov. 30, 2016, 10:15 a.m. - 5:00 p.m. (CET)
Poster Title: Discovery of novel menin-MLL small molecule inhibitors that display high potency and selectivity in vitro and in vivo
Session: Epigenetic modulators
Abstract Number: 264
Poster Location: P090, ICM – Internationales Congress Center München

Date & Time: Dec. 1, 2016, 10:15 a.m. - 5:00 p.m. (CET)
Poster Title: KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics
Session: Molecular targeted agents II
Abstract Number: 381
Poster Location: P060, ICM – Internationales Congress Center München

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL program. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.

GlobeNewswire
globenewswire.com

Last updated on: 15/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.